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1) Internal Medicine Department and 2) Department of Chest Diseases, Hospital Universitario de Burgos, Burgos, SpainAbstractWhether persistent or chronic Q fever may act as a risk factor for stroke is unknown. A case-control study was conducted in the Hospital
Universitario de Burgos (Spain) between February 2011 and December 2012. A total of 803 samples from 634 consecutive hospitalized
patients 65 years old were tested, of whom 111 were cases (patients with prevalent or incident ischaemic stroke and/or transient
ischaemic attack) and 523 were controls (patients without ischaemic stroke and/or transient ischaemic attack). Immunoglobulin G (IgG)
antibody titres phase I and II against Q fever, and IgG antibodies levels against Chlamydia pneumoniae and cytomegalovirus (CMV), were
determined using immunoﬂuorescence assay and ELISA methods, respectively. Phase I IgG titres against Coxiella burnetii 1:256
(compatible with chronic or persistent Q fever) were detected in 16 of 110 (14.5%) cases and in 32 of 524 (6.1%) controls; P = .004,
odds ratio (OR) 2.6, 95% conﬁdence interval (CI) 1.3 to 4.9. This ratio was maintained after adjusting for age, sex, hypertension,
dyslipidaemia, cardioembolic focus, smoking, diabetes, other cardiovascular diseases, C-reactive protein, and leukocyte count (OR 2.6,
95% CI 1.3 to 5.3). High-titre IgG antibodies (top quartile) against CMV (OR 2.1, 95% CI 1.3 to 3.5), but not against C. pneumoniae (OR
0.9, 95% CI 0.5 to 1.6), also were associated with ischaemic stroke after adjustment for risk factors. In conclusion, serology compatible
with persistent or chronic Q fever is associated with ischaemic stroke in elderly patients. High levels of IgG antibodies against CMV, but
not against C. pneumoniae, also are associated with ischaemic stroke in these patients.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: sgq414444@gmail.comIntroductionStroke is one of the leading causes of death worldwide. How-
ever, the occurrence of stroke in populations is incompletely
explained by traditional vascular risk factors [1]. Case-control
and prospective studies indicate that infection with a persis-
tent pathogen, such as Chlamydia pneumoniae or cytomegalo-
virus, might increase stroke risk, although considerable
variation exists in the results [2–11]. These types ofMicrobiol Infect 2015; 21: 362–367
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.028microorganisms are never completely cleared from the host,
and as a result, they could reactivate and promote and/or
worsen atherosclerosis. Furthermore, a causal role for infec-
tion in stroke is supported by multiple pathophysiological
pathways linking infection and inﬂammation, thrombosis, and
stroke [12].
Coxiella burnetii is a strict intracellular pathogen causing Q
fever, a worldwide zoonosis with an extensive animal reservoir
[13]. In humans, it can cause a self-limited ﬂu-like illness,
pneumonia, and hepatitis, but a large proportion of cases are
asymptomatic [13]. Chronic Q fever infections are frequently
associated with cardiovascular complications, mainly valvular
endocarditis [13,14], but can also be associated with aortic
aneurysms and vascular-graft infection [15]. This addition to the
group of potential pathogens involved in cerebrovascularious Diseases. Published by Elsevier Ltd. All rights reserved
CMI González-Quijada et al. Persistent Q fever and ischaemic stroke 363disease is fully justiﬁed. If it is due to a germ of intracellular
growth [16], it can persist in the body for long periods of time
[14], reactivated in case of immunosuppression [16] or preg-
nancy [17], and promote inﬂammation, thrombosis, and
embolus in vascular beds [13–15].
The elderly have an increased risk of stroke [1], aswell as a high
prevalence of seropositivity against Coxiella burnetii, especially in
areas where the infection is endemic [13]. Age also promotes
changes in the immune and inﬂammatory systems that could
produce the persistence or reactivation of certain infections,
such as Q fever [18–23]. However, there are no studies that
speciﬁcally analyse a possible association between stroke and
these infections in elderly subjects, or any other age range.
To clarify this issue, the association between prevalent or
incident stroke and antibody titres compatible with persistent
or chronic Q fever was examined in a large sample of hospi-
talised elderly patients. Secondarily, we also analysed a possible
association between cerebrovascular disease and C. pneumoniae
and cytomegalovirus serology at different serological levels.MethodsPatients
“Association between serological evidence of past Coxiella bur-
netii infection and atherosclerotic cardiovascular disease in
elderly patients” was a study recently conducted by our group
in Hospital Universitario de Burgos (Spain). Details of the
recruitment and patient selection have been published previ-
ously [23]. The current study is an extension of a previous one,
focusing on ischaemic stroke and persistent or chronic Coxiella
burnetii infection, and conducted by expanding the sample (454
to 634 patients according to the size of the sample calculated),
serology immunoglobulin G (IgG) antibody titres phase I against
Q fever, and new secondary data.
Data collection and cardiovascular risk factors
Patients with prevalent or incident ischaemic stroke and/or
transient ischaemic attack were cases, and those without evi-
dence of ischaemic stroke and/or transient ischaemic attack
were controls. As a result, sera from 803 patients were tested
between February 2011 and June 2013, of whom 111 were
cases and 523 were controls. The sample was recruited at a
rate of approximately two patients per day, randomly selected
using a computer program. The study protocol was reviewed
and approved by the Clinical Research Ethics Committee of this
hospital, and the patients signed an informed consent form
(adapted to the Declaration of Helsinki principles).
Ischemic Stroke was considered present if there was sudden
onset of a localizing neurological deﬁcit lasting for 24 hoursClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology(Transient Ischaemic Attack if less than 24 hours), in the
absence of intracranial hemorrhage (assessed by CT scan or
magnetic resonance imaging) and other disease processes
causing focal brain deﬁcits [1]. Prevalent or incident ischaemic
stroke and/or transient ischaemic attack was only considered
valid if it was supported by imaging techniques, or if not avail-
able, was veriﬁed by neurology or internal medicine specialists.
None of the physicians who classiﬁed the patients knew the
serological results beforehand. Furthermore, our laboratory
was not aware of the source of the samples, nor did it have any
clinical information about them.
The control variables used were age, sex, hypertension,
dyslipidaemia, cardioembolic focus, smoking, diabetes, other
cardiovascular diseases, C-reactive protein, and leukocyte
count. It is unknown whether the association at issue may be
inﬂuenced by any of these variables, so it was decided not to
match cases and controls for any of them. A smoker was
someone who was known to have smoked continuously
(several years) at any time in their life. Cardioembolic focus was
deﬁned as the presence of any cardiac pathology capable of
originating emboli [1]. The presence of atrial ﬁbrillation/ﬂutter,
or other known sources of cardiac emboli, such as valvular
prosthesis, valve diseases, dilated cardiomyopathy, and others
[1], was conﬁrmed by two separate specialists. C-reactive
protein may be involved in the activation of the inﬂammatory
system and coagulation, and elevated plasma C-reactive protein
levels signiﬁcantly predict the risk of future ischaemic stroke
and transient ischaemic attack in the elderly subjects [24]. In
addition, relative elevations in white cell count are indepen-
dently associated with an increased risk of future ischaemic
stroke and other cardiovascular events [25].
Serological determinations
Blood samples were collected by venepuncture, and serum
samples were stored at −20°C until analysis. IgG antibody titres
phase I and II against Coxiella burnetii were determined by
immunoﬂuorescence assay using reagents and test protocols
from Focus Technologies (formerly MRL, Cypress, CA, USA). In
the presence of signiﬁcant phase I IgG titres (antibody titres
1:256), persistent or chronic Q fever cannot be ruled out [14].
The same blood determinations was used to determine IgG
antibody levels against C. pneumoniae and cytomegalovirus
(CMV) (using commercial enzyme-linked immunosorbent assay
[ELISA] kits), C-reactive protein (CRP), and other biochemistry
and haematology parameters. An index >1.1 for C. pneumoniae
and 7 for CMV were considered positive.
Determination of sample size and statistical analysis
The determination of sample size was performed based on the
percentage of cases with IgG phase I titres against Coxiellaand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 362–367
TABLE 1. Characteristics of cases and controls
Characteristics
Cases Controls
P value(n [ 111) (n [ 523)
Age 81.6 (7.6) 80.6 (7.5) .24
Men 66 (60.0) 270 (51.5) .11
Caucasian ethnicity 109 (99.3) 520 (99.1) 1.00
Diabetes 51 (46.4) 264 (50.4) .46
Hypertension 87 (79.1) 368 (70.2) .06
Dyslipidaemia 46 (41.8) 223 (42.6) .91
Cardioembolic focus 69 (62.7) 210 (40.1) <.001
Smoking 44 (40.0) 212 (40.5) 1.00
C-reactive protein (mg/L) 47 (58) 53 (68) .52
Albumin (g/dL) 2.87 (0.6) 2.83 (0.6) .54
White blood cells, × 103 9.2 (5.1) 8.2 (4.1) .03
Other cardiovascular diseases
Coronary heart disease 23 (20.9) 92 (17.6) .41
364 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIburnetii 1:256. This percentage was 8% in the ﬁrst 51 patients
tested; along with the ratio between cases and controls (about
1:5), an expected odds ratio (OR) of 2.5 or more, with an α risk
of 5% and a β of 10% (90% power of the study), and a 2-tailed
hypothesis, gives a minimum of 103 cases. Logistic regression
analysis was used to test for a possible relationship between
antibody levels of pathogens and ischaemic stroke, taking into
account the control variables mentioned previously. The data
were analysed using the statistics program SPSS 15.0 (SPSS,
Chicago, IL). The OR was calculated with a conﬁdence interval
of 95%. The statistical tests were considered signiﬁcant for
values of P < .05.Peripheral artery disease 21 (19.1) 45 (8.6) .003
Congestive heart failure 29 (26.4) 166 (31.7) .30
Cardiac valve diseases 24 (21.8) 72 (13.7) .04
Vascular grafts 4 (3.6) 9 (1.7) .25ResultsOther comorbidities
Neoplasm (any)* 18 (16.4) 132 (25.2) .05
Chronic pulmonary disease 30 (27.3) 144 (27.5) 1.00
Dementia 17 (15.5) 89 (17.0) .77
Moderate to severe renal disease 4 (3.6) 17 (3.2) .77
Liver disease 1 (0.9) 17 (3.2) .54
Connective tissue disease 2 (1.8) 15 (2.9) .89
Causes of hospitalization
Respiratory infection 18 (16.2) 90 (17.2) .89
Urinary tract infection 4 (3.6) 33 (6.3) .37
Other infections 8 (7.2) 54 (10.3) .38
Atherosclerotic cardiovascular
disease†
11 (9.9) 16 (3.1) .003
Heart failure and other
cardiovascular diseases
18 (16.2) 84 (16.1) 1.00
Noninfectious lung diseases 9 (8.1) 45 (8.6) 1.00
Fractures and related surgery 8 (7,2) 41 (7.8) 1.00
Complications due to any solid
tumour
2 (1.8) 47 (9.0) .002
Noninfectious or nonmalignant
abdominal diseases
6 (5.4) 43 (8.2) .43
Nephrourologic diseases 3 (2.7) 20 (3.8) .78
Anaemia and other hematologic
diseases
3 (2.7) 14 (2.7) 1.00
Other diseases† 6 (5.4) 36 (6.8) .78
Quantitative variables expressed as mean and standard deviation. Dichotomous
variables expressed in number and (%); Mann-Whitney U or Fisher exact χ2 test
(two-sided), according to the type of variable. Cases, patients with prevalent or
incident ischaemic stroke and/or transient ischaemic attack. Controls, patients
without prevalent or incident ischaemic stroke and/or transient ischaemic attack.
*Haematology tumours included.
†Except stroke.The mean age of the 111 ischaemic stroke cases was 81.6 years
(SD 7.4), of whom 109 (60%) were men. Characteristics of the
case and control subjects are shown in Table 1. Except for the
cardioembolic focus variable, the rest of the stroke risk factors
did not behave as expected. Both groups were similar in terms
of major causes of admission and comorbidities. Of the cases,
27 patients (24.5%) were incident, and 84 (75.5%) were prev-
alent. Of the whole sample, 306 (48.3%) patients had some type
of cardioembolic focus: atrial ﬁbrillation/ﬂutter 279 (91.2%),
valve diseases 96 (31.4%), cardiomyopathy with a low (<30%)
ejection fraction 6 (2%), and mixed causes 75 (24.6%).
The serology is shown in Table 2. All patients with IgG phase
I antibody titres 1:1256 also showed IgG phase II antibody
titres 1:1256. The percentage of patients with signiﬁcant Q
fever titres and high levels of IgG antibodies against CMV (top
quartile) are higher in cases than in controls. However, the
same cannot be said of the different serological cutoff levels
established for C. pneumonia, for which all results were
negative.
The unadjusted and adjusted relationships between Q fever
(IgG phase I  1:256) and C. pneumoniae and CMV (high levels
of IgG) serology and stroke are shown in Table 3. The odds of
Q fever and CMV serology were elevated in isolation and after
adjusting for covariates. None of the stroke risk factors act as a
confounding factor when considered individually or together.
No signiﬁcant interactions between the main dependent vari-
able and covariates were found. Logistic regression analysis
controlled for the covariables (others potential risk factors)
revealed an association between IgG phase I titres  1:256
(compatible with chronic or persistent Q fever) and ischaemic
stroke [OR, 2.6 (95% CI, 1.3–5.3)]. The best predictive model
(logistic regression) was built with three variables: [presence of
cardioembolic focus, serology for Coxiella burnetii (phase I IgG
titres 1:256), and CMV serology (top quartile)], using the
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectstepwise method: [Stroke = −2.29 + 0.81 (OR 2.25, 95% CI
1.43–3.52) + 0.83 (OR 2.29, 95% CI 1.17–4.48) + 0.67 (OR
1.95, 95% CI 1.22–3.12)], respectively, where the number that
precedes the parentheses is the regression coefﬁcient (B) of the
variables included in the equation.DiscussionOriginal tentative attempts to establish a link between Q fever
and vascular disease were reported in a follow-up study of
people infected in a large outbreak of Q fever in Switzerland in
1983 [26]. In this study, the patients who had acute Q fever had
a higher risk of suffering from a cerebrovascular accident andious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 362–367
TABLE 2. Serology of cases and controls
Serology
Cases Controls
P value(n [ 111) (n [ 523)
Coxiella burnetii*
1:256 16 (14.5) 32 (6.1) .004
1:512 5 (4.5) 10 (1.9) .15
1:1024 1 (0.9) 3 (0.6) —
1:2048 1 (0.9) 3 (0.6) —
Chlamydia pneumoniae
Seropositivity 78 (76.5) 363 (75.9) 1.00
Percentil25 65 (63.7) 318 (66.5) .64
Percentil50 44 (43.1) 223 (46.5) .58
Percentil75 19 (18.6) 103 (21.5) .59
Cytomegalovirus .92
Seropositivity 98 (95.1) 455 (92.9) .51
Percentil25 75 (72.8) 366 (74.) .71
Percentil50 53 (51.5) 235 (48.0) .58
Percentil75 37 (35.0) 109 (22.2) .005
Dichotomous variables expressed in number and (%); Fisher exact χ2 test (two-
sided). Cases, patients with prevalent or incident ischaemic stroke and/or transient
ischaemic attack. Controls, patients without prevalent or incident ischaemic stroke
and/or transient ischaemic attack.
*Cutoffs for signiﬁcant phase I immunoglobulin G titres. These patients also showed
phase II immunoglobulin G antibody titres 1:1256.
CMI González-Quijada et al. Persistent Q fever and ischaemic stroke 365ischaemic heart disease after 12 years. Following this line of
research, our group has recently demonstrated an association
between serological markers consistent with past infection by
Coxiella burnetii and cardiovascular disease in elderly hospitalised
patients from a region where the infection is endemic [23].
However, it is unknown whether persistent infection may act in
a similar way, and if any subtype of cardiovascular disease may
be particularly involved in this association. Stroke, for example,
may be a better candidate than other cardiovascular diseases
for this purpose. This is because Coxiella burnetii can participate
in two main pathophysiological mechanisms, cardioembolic and
atherothrombotic, involved in its development [1], the ﬁrst in
the context of valvular endocarditis [13,14] and the other by
infection of vascular atherosclerotic plaques. This second








Coxiella burnetii† + CMV‡ 13.6
Coxiella burnetii† + CMV‡ + Chlamydia‡ 4.6
Cases, patients with prevalent or incident ischaemic stroke and/or transient ischaemic attac
ischaemic attack.
OR, odds ratio (95% conﬁdence interval); CMV, cytomegalovirus.
*Adjusted for sex, age >81 years (yes or no), hypertension (yes or no), dyslipidaemia (yes or
other vascular diseases (yes or no), white blood cells >10 × 103 (yes or no), and C-reactive
†Immunoglobulin G phase I titres 1:256 (compatible with persistent or chronic Q fever).
‡Top quartile of serological values of Chlamydia pneumoniae and CMV.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologybiologically plausible [16–18] but also probable [15]. Further-
more, the presence of this mechanism could explain some of
our results as independence showing this association with the
presence of cardioembolic focus. This mechanism could also
relegate the action of other potential pathogenic factors, such
as anticardiolipin (aCL) antibodies. These autoantibodies have
been involved in acute Q fever, Q fever endocarditis, heart
valve disease, and embolic events in endocarditis from other
causes [18]. Moreover, rapid progression from acute Q fever to
endocarditis is associated with high levels of IgG aCL [18].
However, its pathogenicity appears linked to valvular or
structural heart disease [18], and in our patients this variable is
shown independent of serology in relation to stroke. Regard-
less, it would be interesting to investigate the potential role of
aCL in this issue. Autoimmune phenomena are common in this
infection [13], even in patients with no apparent prior heart
damage [13,15].
Serology alone has limitations when it comes to differenti-
ating between past and present infection with Q fever. As
regards the suspected chronic infection, the acceptable sero-
logical cutoff for phase I IgG titre is  1: 800 [13–15]. How-
ever, one cannot rule out active chronic infection with lower
titres. This fact was proven in cardiovascular samples from 125
patients with suspected chronic Q fever. After performing
serology, culture, and various molecular techniques, it was
found that four suffered Coxiella burnetii endocarditis despite
showing phase I IgG titres <1:800. In accordance with these
results, the authors recommend testing cardiovascular Q fever
infections in all patients with titres of IgG I  200 [14].
Coexistence of high phase II IgG antibody titres, as in our pa-
tients, increases the positive predictive value of the test, and
also its speciﬁcity by reducing the likelihood of cross-reactivity
[13–15].
Human cytomegalovirus is a ubiquitous DNA virus of the
Herpesviridae family that only replicates in humans [21]. It canlla burnetii, Chlamydia pneumoniae, and CMV serology and
Controls
(n [ 523)
Crude OR Adjusted OR*
6.1 2.6 (1.3–4.9) 2.6 (1.3–5.3)
21.5 0.8 (0.4–1.4) 0.9 (0.5–1.6)
22.2 1.8 (1.1–2.9) 2.1 (1.3–3.5)
5.8 2.5 (1.2–5.0) 2.9 (1.4–5.9)
2.7 1.6 (0.6–4.9) 1.8 (0.6–5.5)
k. Controls, patients without prevalent or incident ischaemic stroke and/or transient
no), smoking habits (yes or no), diabetes (yes or no), cardioembolic focus (yes o no),
protein >26 mg/dL (yes or no).
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 362–367
366 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIreactivate and cause severe complications in immunocompro-
mised hosts, and even in immunocompetent hosts [21]. It has
been implicated in transplant vasculopathy [27], atherosclerosis
[5], coronary heart disease [7], and hypertension [28]. Also it
has been implicated in the development of stroke, but with
conﬂicting results [4–7,11]. In our group of patients, a signiﬁ-
cant association was observed between ischaemic stroke and
high levels of IgG antibodies to CMV. The extreme age of our
sample may have inﬂuenced the results through a dual mech-
anism. Chronic CMV infection may contribute signiﬁcantly to T-
cell immunosenescence, and chronic inﬂammation in older
adults [19,29], but also immune and inﬂammatory changes
associated with age may promote reactivation of latent CMV
infection and other persistent pathogens in elderly subjects
[20,29]. CMV IgG assays are very sensitive in determining past
exposure to CMV infection, and seropositivity is a requirement
for CMV reactivation. It remains unclear whether CMV IgG
levels can distinguish between replicating or latent virus.
However, subclinical reactivations of CMV, by CMV DNA
detected in the urine, is associated with increased anti-CMV
antibodies in the blood of elderly patients [21].
Of the three pathogens included in the study, C. pneumoniae
is probably the best studied in relation to stroke [2–10]. Pos-
itive results outweigh the negative ones, but this difference
tends to decrease with age. Elkind et al. found a signiﬁcant as-
sociation between serological evidence of C. pneumoniae
infection and ischaemic stroke in a case-control study with 246
patients and 474 controls with a mean age of 72 years [2].
Bandaru et al. also found a signiﬁcant association between these
two variables in a sample of 100 elderly patients with acute
ischaemic stroke and 100 controls, with a mean age of 74 years
[10]. However, Ngeh et al. failed to ﬁnd one in a study 100
patients and 87 controls with a mean age of 80 years [8].
Something similar happens in 145 patients with ﬁrst ischaemic
stroke and 260 controls with a mean age of 75 years extracted
from the Erlangen Stroke Project [9]. In accordance with these
results, no associations were found in our study between
different serological levels of IgG antibodies to C. pneumoniae
and ischaemic stroke in a sample of patients with a mean age of
nearly 82 years, the largest in this type of study.
Although it is not the purpose to build a predictive model,
nor is the methodology appropriate, we observed that the best
model achieved correctly classiﬁed 83% of cases. This is a very
high ﬁgure, especially when considering that it was achieved
with only three variables: cardioembolic focus, Q fever
serology (signiﬁcant titres), and CMV serology (top quartile).
The traditional risk factors for the development of athero-
sclerosis, such as sex, hypertension, diabetes, smoking habits,
and dyslipidaemia, are excluded from the equation. These re-
sults are not entirely surprising because these factors loseClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectstrength with age [30]. However, it is noteworthy that these
traditional factors can be replaced with variables related to
infectious agents. This ﬁnding is relevant because it shows the
importance that certain infections could have on the develop-
ment of cerebrovascular disease in elderly patients.
In summary, this study is the ﬁrst to report a link between
serological markers of persistent or chronic Q fever and
ischaemic stroke. It is also the ﬁrst to ﬁnd a link between stroke
and CMV serology in an age range in which the activity of the
virus could trigger immunosuppression and reactivation of
other pathogens, or otherwise increase because of it. Further
studies are needed to conﬁrm these data because both in-
fections are susceptible to a speciﬁc prevention and treatment
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